Nxera Pharma Co., Ltd. will place its corporate strategy and near-term objectives before global life sciences investors at the Jefferies London Healthcare Conference, with President and CEO Chris Cargill scheduled for a fireside chat on Monday, 16 November at 4:30 p.m. GMT. The session corresponds to 1:30 a.m. JST on Tuesday, 17 November, according to the Tokyo-listed biopharma company.
The company said Cargill will use the appearance to walk through Nxera’s strategy, recent progress and expected upcoming milestones. The discussion is aimed at an audience of leading international life sciences investors attending the London conference.
Webcast and replay access

Nxera confirmed that the fireside chat will be carried as a live webcast, with a replay available at the same link for 90 days after the event. The company did not disclose further details about the topics Cargill plans to address beyond strategy, progress and milestones.
Company profile and pipeline
Nxera describes itself as a technology-powered biopharma company focused on new specialty medicines for patients with unmet needs in Japan and globally. The company has built what it calls an agile, new-generation commercial business in Japan, where it develops and commercializes innovative medicines, including several launched products, for that market and the broader Asia-Pacific region.
Beyond its commercial operations, Nxera is advancing an extensive pipeline both internally and through partnerships with pharmaceutical and biotechnology companies. That pipeline is powered by the company’s NxWave™ GPCR structure-based drug discovery platform, according to its corporate description.
Nxera operates from Tokyo and Osaka in Japan, London and Cambridge in the United Kingdom, Basel in Switzerland and Seoul in South Korea. Its shares trade on the Tokyo Stock Exchange under ticker 4565.
Investor engagement
The Jefferies London Healthcare Conference appearance adds to a recent run of corporate announcements from Nxera. In the days before the conference notice, the company issued updates on vamorolone’s selection for South Korea’s accelerated reimbursement pilot program for rare disease treatments, a revised consolidated financial forecast for the year ending 31 December 2026, a global license agreement with AbbVie for NXE0033744, and third-quarter 2026 operational highlights and consolidated results.
Nxera also recently announced exclusive rights to the Fabry disease Phase 3 oral therapy candidate lucerastat for Japan and selected Asia-Pacific markets, submitted a marketing authorization application for vamorolone in South Korea for Duchenne muscular dystrophy, and entered an exclusive license, supply and commercialization agreement with Synmosa for QUVIVIQ® (daridorexant) across eight Asia-Pacific markets.
For investors, the fireside chat offers a scheduled opportunity to hear directly from Nxera’s leadership about how those activities fit into the company’s broader strategy and what milestones lie ahead.
